Clinical trials
Metabolic Diseases trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 7 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 3 |
| 89bio, Inc. | 2 |
| Chang Gung Memorial Hospital | 2 |
| Kastle Therapeutics, LLC | 2 |
| Regeneron Pharmaceuticals | 2 |
| 4D Molecular Therapeutics | 1 |
| Chang Gung University of Science and Technology | 1 |
| Fooyin University | 1 |
| Greenyn Biotechnology Co., Ltd. | 1 |
| HoHo Biotech | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Diseases | 23 |
| Diabetes Mellitus | 7 |
| Genetic Diseases, Inborn | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Glucose Metabolism Disorders | 5 |
| Metabolism, Inborn Errors | 5 |
| Endocrine System Diseases | 3 |
| Hyperlipidemias | 3 |
| Lipid Metabolism Disorders | 3 |
| Arthritis | 2 |
Trials
Showing 51 to 23 of 23. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.